BACKGROUND INFORMATION ON THE PROCEDURE 
Submission of the dossier 
The  applicant  GlaxoSmithKline  Biologicals  S.A.  submitted  on  07  March  2006  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Cervarix,  through  the 
centralised  procedure  falling  within  the  Article  3(1)  and  point  1  of  Annex  of  Regulation  (EC)  No 
726/2004 . The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 28 
July 2005  
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
The application submitted is a complete dossier: 
composed of administrative information, complete quality data, non-clinical and clinical data based on 
applicants’ own tests and studies and/or bibliographic literature substituting/supporting certain tests or 
studies. 
The applicant applied for the following indication prevention of cervical cancer. 
Scientific Advice: 
The applicant received Scientific Advice from the CHMP on 17 March 2005. 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur: 
Pieter Neels 
Co-Rapporteur: 
Manfred Haase 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 07 March 2006. 
The procedure started on 29 March 2006.  
The Rapporteur's first Assessment Report was circulated to all CHMP members on 3 July 2006. 
The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 21 June 
2006.  
During  the  meeting  on  24-27  July  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 27 July 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  20 
February 2007. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 6 April 2007. 
During  the  CHMP  meeting  on  23-26  April  2007,  the  CHMP  agreed  on  a  List  of  Outstanding 
issues to be addressed by the applicant. 
During a meeting of the Vaccines Working Party on 2-4 May 2007, experts were convened to 
address questions raised by the CHMP. 
1/2 
©EMEA 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
During the meeting on 16 – 19 July 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Cervarix  on  19  July  2007.  The  applicant  provided  the  letter  of 
undertaking  on  the  follow-up  measures  to  be  fulfilled  post-authorisation  on  17  July  2007  and 
revised later on 23 July 2007. 
2/2 
©EMEA 2007 
 
 
 
 
